Close
FINDING CURES TOGETHER<sup>SM</sup>

San Antonio Breast Cancer Symposium

Dec. 10-14, 2019
Henry B. Gonzalez Convention Center
San Antonio, Texas

Early Registration Deadline: Thursday, Oct. 31, 2019

Codirectors
Carlos L. Arteaga, UT Southwestern Medical Center, Dallas, Texas
Virginia G. Kaklamani, UT Health Science Center at San Antonio, San Antonio, Texas
C. Kent Osborne, Baylor College of Medicine, Houston, Texas

The San Antonio Breast Cancer Symposium® (SABCS®) is a five-day scientific conference attended by an international audience of basic scientists, physician-scientists, clinical investigators and breast care providers, as well as patient advocates seeking an exchange of new information in experimental biology, etiology, prevention, diagnosis, and therapy of premalignant breast disease and breast cancer. SABCS is one of the world’s largest CME meetings driven by a diversity of thought leadership in breast oncology advancements where translational research paired with clinical practice to better understand and treat the disease.

In 2019, SABCS will present two new awards. The Arti Hurria Travel Award was created in memory of Dr. Arti Hurria and in recognition of her commitment to the mentorship and training of the next generation of geriatric oncologists. Five clinical fellows will be named Coltman Scholars in memory of Dr. Charles Coltman, co-founder of SABCS, to commemorate the significant contributions he made to oncology medicine.

Session Topics will Include:

  • Acquired Endocrine Therapy Resistance Beyond ESR1 Mutations
  • Advances in Radiation Therapy for Oligometastatic Breast Cancer
  • Breast Cancer Cell Fate and Plasticity
  • Clinical Prevention: Who to offer what to, and when?
  • CTC Clusters: The Road to Metastasis
  • Developing Novel Therapeutics in the Metastatic Setting
  • Evolving Opportunities to Personalize Radiation Decisions
  • Frontiers in HER Positive Breast Cancer
  • Immunosuppression and the Microenvironment
  • Implementation of Genetic Testing
  • RNA Rewiring
  • Tailoring Therapies Based on Neoadjuvent Response
  • Targeting the Cell Cycle Kinase CDK 4/6 and Beyond